Short Interest in Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) Decreases By 62.7%

Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) was the target of a large decrease in short interest in the month of July. As of July 15th, there was short interest totaling 152,860 shares, a decrease of 62.7% from the June 30th total of 409,938 shares. Based on an average trading volume of 2 shares, the short-interest ratio is currently 76,430.0 days.

Neuren Pharmaceuticals Price Performance

Shares of OTCMKTS:NURPF opened at C$13.46 on Wednesday. The firm has a fifty day moving average price of C$10.72 and a two-hundred day moving average price of C$10.00. Neuren Pharmaceuticals has a one year low of C$7.70 and a one year high of C$14.80.

Neuren Pharmaceuticals Company Profile

Neuren Pharmaceuticals (OTCMKTS:NURPF) is an Australian-based clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders. The company’s research efforts center on addressing unmet medical needs in conditions such as Rett syndrome, Fragile X syndrome and Angelman syndrome. Neuren is publicly traded on the Australian Securities Exchange and maintains an over-the-counter listing in the United States, reflecting its commitment to global capital markets and investor engagement.

The company’s lead candidate, trofinetide (NNZ-2566), is a synthetic analogue of a naturally occurring peptide that has been evaluated in late-stage clinical trials for Rett syndrome and Fragile X syndrome.